Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 7

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 7
---
might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “would” and similar expressions (or the negative version of such words or expressions) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements are based on the current expectations of the management of the Company, as applicable, and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in “ Risk Factors,” those discussed and identified in public filings made with the SEC by the Company and the following:

| ● | changes in the competitive industries and markets in which the Company operates or plans to operate; |

| ● | changes in applicable laws or regulations affecting the Company’s business; |

| ● | the Company’s ability to implement business plans, forecasts, and other expectations after the completion of the Business Combination, and identify and realize additional opportunities; |

| ● | risks related to the Company’s potential inability to achieve or maintain profitability and generate significant revenue; |

| ● | current and future conditions in the global economy, including as a result of economic uncertainty, and its impact on the Company, its business and the markets in which it operates; |

| ● | the Company’s potential inability to manage growth effectively; |

| ● | the Company’s ability to recruit, train and retain qualified personnel; |

| ● | estimates for the prospects and financial performance of the Company’s business may prove to be incorrect or materially different from actual results; |

| ● | costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; |

| ● | risks related to the Company’s marketing and growth strategies; |

| ● | the effects of competition on the Company’s business; |

| ● | expectations with respect to future operating and financial performance and growth, including when the Company will generate positive cash flow from operations; |

| ● | the Company’s ability to raise funding on reasonable terms as necessary to develop its products in the timeframe contemplated by its business plan; |

| ● | the inability to maintain the listing of the Company’s common stock and warrants